-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$94.0028.56% Upside
Recent Analyst Forecasts and Stock Ratings
Intra-Cellular Therapies, Inc. Frequently Asked Questions
-
What analysts cover Intra-Cellular Therapies, Inc.?
Intra-Cellular Therapies, Inc. has been rated by research analysts at Piper Sandler, RBC Capital, Goldman Sachs, Needham, UBS, Mizuho Securities in the past 90 days.